Bayer IUD Could Get Boost From Revised ACOG Guidance On Adolescent Contraception
This article was originally published in The Pink Sheet Daily
Skyla (levonorgestrel-releasing intrauterine system) is the first new IUD to the U.S. market in over a decade; Bayer plans to focus its marketing on women who have not had a child.
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.